ARTICLE LINKS: SERUM ANTI-MULLERIAN HORMONE AND ESTRADIOL LEVELS AS PREDICTORS OF OVARIAN HYPERSTIMULATION SYNDROME IN ASSISTED REPRODUCTION TECHNOLOGY CYCLES.GYNECOLOGY Obstetrical Liu, Chung-Hsien; Huang, Chuin-Chia; Wu, Yi-Ling; Shih, Yang-Tse; Ho, Hong-Nerng; Yang, Yu-Shih; Lee, Maw-Shang _ ABSTRACT: Ovarian hyperstimulation syndrome (OHSS) is a serious and sometimes a life-threateningplication of controlled ovarian stimulation (COS).Difficult to accurately predict OHSS in any particular in vitro fertilization (IVF) treatment cycle.Serum levels of anti-mullerian hormone (AMH) are closely related to the ovarian response or ovarian reserve during IVF cycles.Goal of this study was to determine how reliably the basal serum AMH level predicted OHSS in a prospective cohort of 262 IVF cycles.Women followed a long or short gonadotropin-releasing hormone (GnRH) agonist protocol, and the luteal phase was supported by human chorionic gonadotropin (hCG).Micronized progesterone was given after the serum estradiol level exceeded 3000 pg/mL or more than 15 oocytes were retrieved.Severe OHSS was noted in 8% of patients, only one of whom followed the short GnRH agonist protocol.Overall rate of clinical pregnancy was 41%.Basal serum AMH level predicted OHSS more accurately than either age or body mass index.Sensitivity was 90.Its specificity was 81.Logistic regression analysis identified basal serum AMH (odds ratio, 1.= 0.The serum estradiol level on the day of hCG treatment (odds ratio, 1.0.Significant predictors of OHSS.Logistic regression analysis, the only significant factor predicting clinical pregnancy was age (odds ratio, 0.= 0.Basal serum AMH did not effectively predict clinical pregnancy.Basal serum AMH reliably predicts OHSS and may be used to ensure that patients with high levels receive a mild, patient-friendly protocol for ovarian stimulation.Lippincott Williams & Wilkins, Inc.2008, Lippincott Williams & Wilkins.Rights reserved.By Lippincott Williams & Wilkins.Read more Dcep chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients
Get more Safety of anticoagulation use and bevacizumab in patients with glioma
